Caris Life Sciences is a leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare.

Caris Life Sciences is revolutionizing precision medicine to provide physicians and patients with the highest quality information about their health.

Caris Life Sciences was founded in 2008 by David D. Halbert. The company is headquartered in Irving, Texas, with offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland.

Caris' comprehensive molecular profiling approach precisely analyzes DNA (Whole Exome Sequencing), RNA (Whole Transcriptome Sequencing), and protein biomarkers to reveal a patient's molecular blueprint for selecting the most appropriate therapies.

Caris is actively developing a better understanding of the molecular mechanisms of cancer by leveraging its proprietary AI analytics engine, DEAN™, across its extensive catalog of molecular intelligence and clinical outcomes data.

Caris also introduced Caris Assure™, a blood-based molecular profiling assay providing deep molecular insights from a simple blood sample. Caris Assure™, a minimally invasive liquid biopsy option for biomarker analysis and serial monitoring of cancer patients. The Caris Discovery, is a proprietary, multi-omics target discovery engine designed to identify novel targets for drug development.

Caris has molecular database of over 455,000 tumor profiles to date, including more than 350,000 profiles with matched molecular data and clinical outcomes. Caris has established itself among physicians, patients, and biopharma partners as a trusted provider and innovator.

Caris is backed by Highland Capital Management, Coatue, Sixth Street, T. Rowe Price Associates, OrbiMed, Silver Lake, Fidelity Management & Research Company, Braidwell, and others. The company secured $400M in a senior debt facility on Jan 19, 2023. This brings Caris' total funding to $1.7B to date. Caris was valued at $7.83B in its $830M financing raised in May 2021.